The expert panel provides a comprehensive overview of the COSMOS-CRC-03 study and touch on the importance of also looking at real-world data.
ME-344/Bevacizumab Combo Shows Early Efficacy in mCRC
ME-344 and bevacizumab can now have an additional 20 patients enrolled on the phase 1b trial for relapsed metastatic colorectal cancer.
Joleen Hubbard, MD, Highlights The “Exciting Space” Of Metastatic CRC
New studies and treatment options prove to be effective in treating metastatic CRC, notes Joleen Hubbard, MD.
Adagrasib Combo Yields Encouraging Responses in KRAS G12C–Mutated CRC
Data from the phase 1/2 KRYSTAL-1 trial may support adagrasib plus cetuximab as a new standard in previously treated metastatic KRAS G12C–mutated CRC.
Tanios S. Bekaii-Saab, MD, Speaks to Expanding Horizons in CRC Treatment
Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.
CRC-Associated Gene Alteration May Raise Likelihood of Other Solid Tumors
If possible, targeting the BER pathway for drug sensitivities may increase therapeutic options for managing solid cancers, wrote Channing Paller, MD.
Personalized Vaccine Yields Early PFS Benefit in Metastatic MSS-CRC
Long-term circulating tumor DNA responses appear to align with progression-free survival trends in a phase 2/3 trial of the GRANITE vaccine in those with microsatellite-stable colorectal cancer.